Palladium (II) complex and thalidomide intercept angiogenic signaling via targeting FAK/Src and Erk/Akt/PLC gamma dependent autophagy pathways in human umbilical vein endothelial cells

Aydinlik S., ÜVEZ A., Kiyan H. T., Gurel-Gurevin E., YILMAZ V. T., Ulukaya E., ...More

MICROVASCULAR RESEARCH, vol.138, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 138
  • Publication Date: 2021
  • Doi Number: 10.1016/j.mvr.2021.104229
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Keywords: Palladium complex, Angiogenesis, Autophagy, VEGF pathway, Chick chorioallantoic membrane (CAM), Human umbilical vein endothelial cells (HUVECs), FOCAL ADHESION KINASE, GROWTH-FACTOR RECEPTOR-2, IN-VITRO, PHOSPHOLIPASE C-GAMMA-1, MONOCYTIC LEUKEMIA, DOWN-REGULATION, CANCER CELLS, ACTIVATION, INHIBITION, AKT
  • Karadeniz Technical University Affiliated: No


The current study assessed the effects of the thalidomide and palladium (II) saccharinate complex of terpyridine on the suppression of angiogenesis-mediated cell proliferation. The viability was assessed after treatment with palladium (II) complex (1.56-100 mu M) and thalidomide (0.1-400 mu M) alone by using ATP assay for 48 h. Palladium (II) complex was found to inhibit growth statistically significant in a dose-dependent manner in HUVECs and promoted PARP-1 cleavage through the production of ROS. On the other hand, thalidomide did not cause any significant change in cell viability. Moreover, cell death was observed to be manifested as late apoptosis due to Annexin V/SYTOX staining after palladium (II) complex treatment however, thalidomide did not demonstrate similar results. Thalidomide and palladium (II) complex also suppressed HUVEC migration and capillary-like structure tube formation in vitro in a time-dependent manner. Palladium (II) complex (5 mg/ml) treatment showed a strong antiangiogenic effect similar to positive control thalidomide (5 mg/ml) and suc-cessfully disrupted the vasculature and reduced the thickness of the vessels compared to control (agar). Furthermore, suppression of autophagy enhanced the cell death and anti-angiogenic effect of thalidomide and palladium (II) complex. We also showed that being treated with thalidomide and palladium (II) complex inhibited phosphorylation of the signaling regulators downstream of the VEGFR2. These results provide evidence for the regulation of endothelial cell functions that are relevant to angiogenesis through the suppression of the FAK/Src/Akt/ERK1/2 signaling pathway. Our results also indicate that PLC-gamma 1 phosphorylation leads to acti-vation of p-Akt and p-Erk1/2 which cause stimulation on cell proliferation at lower doses. Hence, we demon-strated that palladium (II) and thalidomide can induce cell death via the Erk/Akt/PLC gamma signaling pathway and that this pathway might be a novel mechanism.